G. Murden

Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians

M. Costantini, D. Merlo, D. Currow, 2022, BMC Pulmonary Medicine.

Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE

C. Faivre-Finn, A. Greystoke, A. Chalmers, 2022, JCO precision oncology.

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

C. Hiley, A. Ryan, C. Faivre-Finn, 2020, Clinical and translational radiation oncology.

Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial.

S. Johnston, D. Dodwell, G. Velikova, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

T. Powles, P. Nathan, N. Vasudev, 2019, BMC Cancer.

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

R. Eastell, C. Twelves, I. Macpherson, 2022, Journal of bone oncology.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

T. Powles, P. Nathan, N. Vasudev, 2019, BMC Cancer.

Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).

D. Cameron, R. Bell, Janet E Brown, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial

B. Farsides, S. Bajwah, M. Krajnik, 2024, The Lancet Respiratory Medicine.